Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
The Swiss M&A market reached record levels in 2025. Swissinfo looks at some of those deals and why they matter.
Generated with artificial intelligence.
This content was published on
May 27, 2026 - 14:08
1 minute
Novartis says Avidity's science could apply beyond muscular dystrophies
Eli Lilly spending $3.8 billion to buy vaccine makers
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Novartis, AbbVie plan summer layoffs on opposite coasts
Eli Lilly acquires three vaccine developers for $3.8 billion
Three vaccine biotechs to be bought by Lilly for up to $3.8B
Ambitious Belgian biotech goes shopping in US 'built to be bought' market | Euractiv
Perché Eli Lilly fa scorpacciata di biotech focalizzate sui vaccini - Startmag
Lilly dives into vaccine research with 3 biotech buyouts
Dans un contexte tendu pour la place pharmaceutique suisse, Bristol-Myers Squibb inaugure une nouvelle usine à plus de 300 millions - Le Temps
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
L’operazione, che riguarda una società specializzata nelle malattie rare, è la più grande acquisizione realizzata sotto la guida…
Operazione tutta in contanti con un premio del 46%. Permette al colosso svizzero di compensare l’imminente scadenza di alcuni…
Novartis raggiunto un accordo per l'acquisizione della statunitense Avidity Biosciences, specializzata nelle terapie Rna per…
Der schweizerische Pharmakonzern will sein Wachstum sichern. Und die sogenannte Patentklippe überspringen.
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
